References
- Tian L, Qiang T, Liang C, et al. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. Eur J Med Chem. 2021 5;213:113201. DOI:https://doi.org/10.1016/j.ejmech.2021.113201.
- Nili A, Farbod A, Neishabouri A, et al. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. Rev Med Virol. 2020;30:1–13.
- Pardo J, Shukla AM, Chamarthi G, et al. The journey of remdesivir: from Ebola to COVID-19. Drugs Context. 2020;9:2020-4-14.
- Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaal3653.
- Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14(4):397–412.
- Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. DOI:https://doi.org/10.1038/s41467-019-13940-6.
- Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. DOI:https://doi.org/10.1056/NEJMoa2001191.
- Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;382(24):2327–2336. DOI:https://doi.org/10.1056/NEJMoa2007016.
- El-Sayed A, Kamel M. Coronaviruses in humans and animals: the role of bats in viral evolution. Environ Sci Pollut Res Int. 2021;28(16):19589–19600.
- Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003;362:1353–1358.
- Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276–278.
- Yu ITS, Wong TW, Chiu YL, et al. Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2005;40:1237–1243.
- Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003;168:1449–1456.
- Mazzulli T, Farcas GA, Poutanen SM, et al. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg Infect Dis. 2004;10:20–24.
- Müller MA, Corman VM, Jores J, et al. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997. Emerg Infect Dis. 2014;20:2093–2095.
- Middle East Respiratory Syndrome Coronavirus. World Health Organization. 2019. [cited 2021 May 15]. Available online: http://www.who.int/emergencies/mers-cov/en/.
- Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160(6):389–397. DOI:https://doi.org/10.7326/M13-2486.
- Zumla A, Hui DS, Perlman S, et al. Middle East respiratory syndrome. Lancet. 2015;386(9997):995–1007. DOI:https://doi.org/10.1016/S0140-6736(15)60454-8.
- Rodriguez-Morales AJ, Bonilla-Aldana DK, Balbin-Ramon GJ, et al. History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic. Infez Med. 2020;28:3–5.
- Al-Raddadi RM, Shabouni OI, Alraddadi ZM, et al. Burden of Middle East respiratory syndrome coronavirus infection in Saudi Arabia. J Infect Public Health. 2020;13(5):692–696. DOI:https://doi.org/10.1016/j.jiph.2019.11.016.
- Onder G, Rezza G, Brusaferro S, et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323:1775–1776.
- Mann R, Perisetti A, Gajendran M, et al. Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. Front Med. 2020;7:581521.
- Borah P, Deb PK, Chandrasekaran B, et al. Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted. Front Mol Biosci. 2021;8:627723.
- Pagliano P, Spera AM, Ascione T, et al. Infections causing stroke or stroke-like syndromes. Infection. 2020;48(3): 323–332. DOI:https://doi.org/10.1007/s15010-020-01415-6.
- Brouwer MC, Ascione T, Pagliano P, et al. Neurologic aspects of covid-19: a concise review. Infez Med. 2020;28:42–45.
- Du W, Yu J, Wang H, et al. Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China. Infection. 2020;48(3):445–452. DOI:https://doi.org/10.1007/s15010-020-01427-2.
- Fumagalli A, Misuraca C, Bianchi A, et al. Pulmonary function in patients surviving to COVID-19 pneumonia. Infection. 2021;49(1):153–157. DOI:https://doi.org/10.1007/s15010-020-01474-9.
- Pagliano P, Scarpati G, Sellitto C, et al. Experimental Pharmacotherapy for COVID-19: The Latest Advances. J Exp Pharmacol. 2021;13:1–13.
- Esposito V, Verdina A, Manente L, et al. Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J Cell Physiol. 2013;228(3):640–645. DOI:https://doi.org/10.1002/jcp.24173.
- Bellera CL, Llanos M, Gantner ME, et al. Can drug repurposing strategies be the solution to the COVID-19 crisis?. Expert Opin Drug Discov. 2021;16:605–612.
- Cho A, Saunders OL, Butler T, et al. Synthesis and antiviral activity of a series of 1ʹ-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett. 2012;22:2705–2707.
- Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785–6797. DOI:https://doi.org/10.1074/jbc.RA120.013679.
- Kotta S, Aldawsari HM, Badr-Eldin SM, et al. Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. Front Mol Biosci. 2020 Nov 17;7:606393. DOI:https://doi.org/10.3389/fmolb.2020.606393. PMID: 33282914; PMCID: PMC7705351.
- Siegel D, Hui HC, Doerffler E, et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017;60:1648–1661.
- Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594): 381–385. DOI:https://doi.org/10.1038/nature17180.
- Mulangu S, Dodd LE, Davey RTJ, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019;381(24): 2293–2303. DOI:https://doi.org/10.1056/NEJMoa1910993.
- Kokic G, Hillen HS, Tegunov D, et al., Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun. 2021;12(1): 279. DOI:https://doi.org/10.1038/s41467-020-20542-0.
- Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.
- Subissi L, Posthuma CC, Collet A, et al. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci U S A. 2014;111(37):E3900–9. DOI:https://doi.org/10.1073/pnas.1323705111.
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020:269–271. DOI:https://doi.org/10.1038/s41422-020-0282-0.
- Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018;9:e00221-18.
- Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020;32(3):107940. DOI:https://doi.org/10.1016/j.celrep.2020.107940.
- Hanafin PO, Jermain B, Hickey AJ, et al. A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. CPT Pharmacometrics Syst Pharmacol. 2021;10(2):89–99.
- Ko M, Jeon S, Ryu W-S, et al. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021;93(3):1403–1408.
- Levine MM. Monoclonal Antibody Therapy for Ebola Virus Disease. N Engl J Med. 2019:2365–2366. DOI:https://doi.org/10.1056/NEJMe1915350. United States.
- Hu W-J, Chang L, Yang Y, et al. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. Acta Pharmacol Sin. 2021;42:1195-12 .
- Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824): 273–276. DOI:https://doi.org/10.1038/s41586-020-2423-5.
- Dobrovolny HM. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2. Virology. 2020;550:61–69.
- Martinez DR, Schaefer A, Leist SR, et al. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice- Cell Rep 2021; 36:109450. .
- Xie J, Wang Z. Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs?An in vitro and in vivo DMPK assessment. Acta Pharm Sin B2021;11:1607-1616.https://www.sciencedirect.com/science/article/pii/S2211383521001003.
- Humeniuk R, Mathias A, Cao H, et al. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. Clin Transl Sci. 2020;13:896–906.
- Aleissa MM, Silverman EA, Paredes Acosta LM, et al. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. Antimicrob Agents Chemother. 2020;65:e01814-01820.
- Xu Y, Barauskas O, Kim C, et al. Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent. Antimicrob Agents Chemother. 2021;65:02237-20.
- COVID-19 treatment guidelines. NIH. 2021. Available at: [Last accessed 21 April 2021]. https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/.
- Kumar D, Trivedi N. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomed Pharmacother. 2021;139:111642.
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383:1813–1826. DOI:https://doi.org/10.1056/NEJMoa2007764.
- Spinner CD, Gottlieb RL, Criner GJ, et al., Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(11): 1048–1057. DOI:https://doi.org/10.1001/jama.2020.16349.
- Okoli GN, Rabbani R, Copstein L, et al. Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Infect Dis (London, England). 2021;53:691-699.
- Piscoya A, Ng-Sueng LF, Parra Del Riego A, et al. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PLoS One. 2020;15(12): e0243705. DOI:https://doi.org/10.1371/journal.pone.0243705.
- Rezagholizadeh A, Khiali S, Sarbakhsh P, et al. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur J Pharmacol. 2021;897:173926. DOI:https://doi.org/10.1016/j.ejphar.2021.173926.
- Rodriguez-Morales AJ, Balbin-Ramon GJ, Rabaan AA. Genomic Epidemiology and its importance in the study of the COVID-19 pandemic. Infez Med. 2020;28:139–142. Italy.
- Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):e9. DOI:https://doi.org/10.1016/j.cell.2021.03.013.
- COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19. [cited 2021 Jul 15]. Available at: https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized#:~:text=In%20May%202020%2C%20the%20FDA,patients%20with%20severe%20COVID%2D19
- FDA Approves First Treatment for COVID-19. [cited 2021 Jul 15]. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid–19
- WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, etal. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497–511.
- Tasavon Gholamhoseini M, Yazdi-Feyzabadi V, Goudarzi R, et al. Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2021;24:237–245.
- Singh S, Khera D, Chugh A, et al. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open. 2021;11(6): e048416. DOI:https://doi.org/10.1136/bmjopen-2020-048416.
- Pagliano P, Sellitto C, Conti V, et al. Characteristics of viral pneumonia in the COVID-19 era: an update. Infection. 2021;29:1–10.